Some batches of Durisan hand sanitizer have been previously recalled and in a new update, the company has further expanded the recall. The U.S. Food and Drug Administration (FDA) explained that the move was due to the fact that the affected hand sanitizers were contaminated with a type of bacteria that could infect the users.
The expanded recall announcement
Based on the FDA’s recall notice that was posted on Tuesday, May 18, Durisan Sanit Technologies updated the recall for its anti-microbial hand sanitizer products. Now, the batches of products to be recalled were expanded to add those that were manufactured after April 10, 2019, and have not expired yet.
The company made the decision because the affected bottles were said to have been contaminated with common bacteria called Burkholderia contaminans. People infected may not experience reactions but for others, they may suffer from more serious effects once the bacteria enter their bloodstream through scrapes or wounds after using the hand sanitizer.
An infection could result from this, as per the FDA. The agency also warned that people with weaker immune systems are more susceptible to infection so the use of the contaminated hand sanitizer is risky.
Other information of the recalled lots
Fox Business mentioned that as per the Centers for Disease Control and Prevention (CDC), Burkholderia cepacia is found in water and soil. This bacteria may also be a little complicated to treat because it is said to be usually resistant to common antibiotics.
In any case, the recalled Durisan hand sanitizer includes 47 lots of the products. These covered the ones packed in various bottle sizes of 18 ml credit cards, 118 ml, 236 ml, 300 ml and 500 ml. The wall-mounted dispensers that use 1000 ml bottles are also included.
Fortunately, there is no report of adverse reactions yet or complaints from customers regarding the contaminated Durisan hand sanitizer. With the voluntary recall of its maker, the FDA said that distributors and retailers were already notified too.
“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using this drug product,” the FDA wrote in the expanded recall announcement. “Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.”


Markets Stay Strong Despite Oil Shock Concerns as Earnings Drive Investor Confidence
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth
Panama Defends Port Takeover Amid U.S.-China Tensions and Canal Dispute
China Manufacturing PMI Beats Forecasts in April Amid Weak Domestic Demand
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Dollar Holds Near Two-Week High as Fed Hawkish Shift Lifts Yields, Yen Near Intervention Zone
Yen Weakens After Intervention Spike as Dollar Stabilizes Amid Global Tensions
Oil Prices Surge Amid U.S.-Iran Tensions and Supply Disruption Fears
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Oil Prices Fall as Iran Proposes New Deal Amid Ongoing U.S. Tensions
Gold Prices Hold Steady as Iran War and Interest Rate Outlook Weigh on Markets
US Stock Futures Mixed as Fed Holds Rates, Oil Prices Surge, and Big Tech Earnings Drive Market Moves
EU Warns of Response as U.S. Considers 25% Tariffs on Car Imports
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 



